Xanthopoulos Kleanthis Gabriel 4

What Happened
Dr. Xanthopoulos Kleanthis Gabriel, a non-employee director of Connect Biopharma Holdings Ltd (CNTB), was granted 2,816 fully vested ordinary shares on March 31, 2026 as part of the company's non-employee director compensation program. The Form 4 reports the shares at $0.00 per share (code A — award/grant) because they were issued in lieu of a portion of his cash retainer rather than bought on the open market.

Key Details

• Transaction date: 2026-03-31 (reported on Form 4 filed 2026-04-02).
• Transaction type/code: Award/Grant (A). Reported price per share: $0.00 (shares issued in lieu of cash).
• Shares issued: 2,816 fully vested ordinary shares.
• Shares owned after transaction: Not specified in this Form 4.
• Footnote: Shares were issued under the Connect Biopharma Non-Employee Director Compensation Program; the number granted was calculated by dividing the applicable equity value by the 30-day average closing price up to March 31, 2026, rounded down.
• Filing timeliness: Filed April 2, 2026 — appears timely under Section 16 filing rules (within two business days).

Context
This was a routine director compensation award (shares in lieu of cash), not an open-market purchase or sale. Such awards are standard compensation and do not, by themselves, indicate the director buying or selling stock for investment purposes.